Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Lymphoma Clear all
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Childhood Solid Tumor, Childhood Lymphoma, Relapsed Cancer, Refractory Cancer, Adult Solid Tumor, Adult Lymphoma
Interventions
Pembrolizumab, Decitabine, Hypofractionated Index Site Radiation
Drug · Radiation
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 7:19 PM EDT
Suspended Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis), Chronic Myeloid Leukemia - Accelerated Phase
Interventions
Orca-Q
Biological
Lead sponsor
University of Florida
Other
Eligibility
Up to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 7:19 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Soft Tissue, Lymphoma, Osteosarcoma
Interventions
PET/MR imaging, MR imaging, PET/CT imaging
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
Up to 40 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
Interventions
Decitabine, Vorinostat, Vincristine, Dexamethasone, Mitoxantrone, Pegaspargase, Methotrexate
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Leukemia-Lymphoma
Interventions
EMLA, Lidocaine
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced May 21, 2026, 7:19 PM EDT
Enrolling by invitation Phase 2 Interventional
View directory record Official record
Conditions
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma
Interventions
AUTO CAR T cell therapy
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Pediatric Cancer
Interventions
Epratuzumab, Fludarabine, Cyclophosphamide, Mesna, Infusion of NK cells, Interleukin-2
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced May 21, 2026, 7:19 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Pediatric ALL
Interventions
SM-THINk
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 100 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced May 21, 2026, 7:19 PM EDT
Active, not recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced May 21, 2026, 7:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions
Elimusertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 30 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 21, 2026, 7:19 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Electronic Health Record Review, Interview, Survey Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
39
States / cities
Oakland, California • Wilmington, Delaware • Fort Lauderdale, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 21, 2026, 7:19 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Stanford V Chemotherapy, Radiation Therapy
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
6
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced May 21, 2026, 7:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Interventions
JCAR017, Lymphodepleting, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Celgene
Industry
Eligibility
Up to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Duarte, California • Redwood City, California • St. Petersburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced May 21, 2026, 7:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Anemia, Healthy, Pediatric ALL
Interventions
Rad-67 Pulse oximeter
Device
Lead sponsor
Masimo Corporation
Industry
Eligibility
1 Month and older
Enrollment
447 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
7
States / cities
Burbank, California • Irvine, California • Lake Forest, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced May 21, 2026, 7:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
Interventions
Neratinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Panobinostat, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
8 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced May 21, 2026, 7:19 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
Interventions
CD30.CAR-T, Fludarabine, Bendamustine
Drug
Lead sponsor
Tessa Therapeutics
Industry
Eligibility
12 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2037
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Leukemia
Interventions
temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
14
States / cities
Stanford, California • Indianapolis, Indiana • Minneapolis, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced May 21, 2026, 7:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Pediatric ALL, Motility Disorder
Interventions
patient education document
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 11 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced May 21, 2026, 7:19 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Allopurinol
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 30 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
alvocidib, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
Relatlimab, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced May 21, 2026, 7:19 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Pediatric ALL, Cancer
Interventions
IPAD, Augmented Reality
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
5 Years to 15 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced May 21, 2026, 7:19 PM EDT